HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yukito Ichinose Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ichinose, Y. Articles by Takanashi, N. Search for Related Content PubMed PubMed Citation Articles by Ichinose, Y. Articles by Takanashi, N.

J Thorac Cardiovasc Surg 1994;108:158-161
© 1994 Mosby, Inc.

GENERAL THORACIC SURGERY

Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection

Fukuoka, Japan

Supported in part by a grant in aid for Cancer Research (62-S-1 and 2-S-1) from the Ministry of Health and Welfare, Japan.

Received for publication Oct. 1, 1993. Accepted for publication Dec. 14, 1993. Address for reprints: Y. Ichinose, MD, Department of Chest Surgery, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka 815, Japan.

Abstract

The postrecurrent survival of 215 patients who had undergone a complete resection of non-small-cell lung cancer was examined on the basis of various factors, which included gender (female, male), age (<65,65), the pathologic stage of disease at the time of operation (I, II, III), histologic type (squamous cell, nonsquamous cell carcinoma), type of operation (pneumonectomy, other), the selection of adjuvant treatment before recurrence (no treatment, mild chemotherapy, intensive chemotherapy and/or radiotherapy), recurrent site (local, distant), and the disease-free interval (365, 365 days). A univariate analysis of the postrecurrent survival showed that the significant factors influencing the survival consisted of gender, pathologic stage, recurrent site, selection of adjuvant treatment, and the disease-free interval. Namely, female patients or patients who had pathologic stage I disease, local recurrence, no adjuvant treatment, or a disease-free interval of more than 365 days would be expected to have a prolonged survival after recurrence. Of the five significant factors, only two factors (gender and the selection of the adjuvant treatment) were found to be predominant postrecurrent prognostic factors by multivariate analysis. These observations suggest that the biologic behavior of a recurrent tumor may therefore be influenced by gender and adjuvant treatment before recurrence. (J THORAC CARDIOVASC SURG1994;108:158-61)

This article has been cited by other articles:

				T. Nakagawa, N. Okumura, K. Ohata, H. Igai, T. Matsuoka, and K. Kameyama Postrecurrence survival in patients with stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 499 - 504. [Abstract] [Full Text] [PDF]

				H. Sugimura, F. C. Nichols, P. Yang, M. S. Allen, S. D. Cassivi, C. Deschamps, B. A. Williams, and P. C. Pairolero Survival After Recurrent Nonsmall-Cell Lung Cancer After Complete Pulmonary Resection Ann. Thorac. Surg., February 1, 2007; 83(2): 409 - 418. [Abstract] [Full Text] [PDF]

				H. Sugimura and P. Yang Long-term Survivorship in Lung Cancer: A Review. Chest, April 1, 2006; 129(4): 1088 - 1097. [Abstract] [Full Text] [PDF]

				B. A. Williams, H. Sugimura, C. Endo, F. C. Nichols, S. D. Cassivi, M. S. Allen, P. C. Pairolero, C. Deschamps, and P. Yang Predicting Postrecurrence Survival Among Completely Resected Nonsmall-Cell Lung Cancer Patients Ann. Thorac. Surg., March 1, 2006; 81(3): 1021 - 1027. [Abstract] [Full Text] [PDF]

				M. K. Ferguson and A. G. Lehman Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques Ann. Thorac. Surg., December 1, 2003; 76(6): 1782 - 1788. [Abstract] [Full Text] [PDF]

				M. Kara, Y. Ohta, Y. Tanaka, M. Oda, and Y. Watanabe Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer Ann. Thorac. Surg., March 1, 2001; 71(3): 944 - 948. [Abstract] [Full Text] [PDF]

				P. Granone, L. Trodella, S. Margaritora, A. Cesario, G. M. Corbo, G. Mantini, M. Balducci, and G. Fumagalli Radiotherapy versus follow-up in the treatment of pathological stage Ia and Ib non-small cell lung cancer. Early stopped analysis of a randomized controlled study Eur. J. Cardiothorac. Surg., October 1, 2000; 18(4): 418 - 424. [Abstract] [Full Text] [PDF]

				R. Lenner, A. S. Teirstein, and D. J. Krellenstein Metachronous cancers or late recurrences after resection of stage I lung cancer Ann. Thorac. Surg., February 1, 1999; 67(2): 548 - 549. [Abstract] [Full Text] [PDF]